44 results about "Microvesicles" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

To provide novel strategies to control cytokine release syndromes, and especially cytokine storms.SOLUTION: Embodiments of the disclosure include methods and compositions related to treatment and prevention of an excess of cytokines in an individual using fibroblasts or fibroblast-derived microvesicles. In particular embodiments, there are methods and compositions for treating and preventing toxicities in an individual that may be the result of cytokine release syndrome. In specific cases, an individual is treated for cytokine release syndrome with fibroblasts having one or more specific markers.SELECTED DRAWING: Figure 1

A device, system and process involve conducting electroporation of microvesicles or exosomes or other target structures in a microfluidic arrangement at pressures that exceed atmospheric pressure. Single as well as multiple flow configurations can be employed. In some cases, the system and its operation are computer-controlled for partial or complete automation.

The invention relates to a method of enriching Muse cells and obtaining the exosomes, microvesicles, or the secretome therefrom, in several embodiments, the exosomes, microvesicles, secretome or Muse cells may be used in therapeutic methods or non-therapeutic methods.

The present invention discloses a transfersome complex sugar microneedle patch and a preparation method and application thereof, belonging to the field of microneedle technology, and the method comprises: adding a transfersome to a monosaccharide or disaccharide solution, fully mixing to obtain a transfersome-sugar solution, using the transfersome-sugar solution to fill the needle body part of a microneedle mold, drying to obtain the needle body, and then using a polymer solution to continue filling the remaining part of the microneedle mold, drying to obtain the transfersome complex sugar microneedle patch; wherein the transfersome includes cell exosomes, cell microvesicles, apoptotic bodies or liposomes, etc. The transfersome complex sugar microneedle patch prepared by the method of the present invention can maintain the structure and biological function of the transfersome for a long time, and has broad application prospects in the fields of drug delivery, medical treatment, health care or beauty.

The present invention provides methods of detecting breast cancer or breast cancer cells comprising: (a) obtaining a liquid sample from a subject which sample comprises cells, microvesicles and / or exosomes; and (b) determining the presence of soluble or cell surface associated Cyr61 in the sample; wherein the liquid sample is selected from blood, and / or bone marrow aspirate and wherein the determination of the presence of Cyr61 comprises detection via ELISA.

The present invention relates to a secretome-based biomaterial, wherein the secretome is cell secretome selected from secreted soluble factors, apoptotic bodies, small extracellular vesicles or microvesicles that are released from cells of therapeutic interest to the cell culture medium or other fluids or combinations thereof. The invention further relates to a method for the production of the secretome-based biomaterial and to the use thereof for the treatment of diseases requiring tissue regeneration and / or immunomodulation.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Means of rejuvenating a subject through exposure to soluble factors or cell-free means, wherein the soluble factors are elaborated by immature or tolerogenic cells, and wherein the soluble factors comprise peptides, proteins, nucleic acids, microvesicles, nanovesicles, apoptotic bodies, and exosomes. Administration of the soluble factors is regenerative and to treat or prevent diseases associated with aging. Ultrasound can be utilized to enhance uptake, wherein said ultrasound may be delivered through extracorporeal shock wave therapy or other means. Cell secretions comprising soluble factors are collected from a bioreactor in which immature cells are viable in a basal state or stimulated by inflammatory or age-associated stimuli.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

This present disclosure relates to the use of donor organ-derived microvesicles to monitor the status of a transplanted organ in a subject. Accordingly, this disclosure provides for methods and kits for isolating, purifying and / or identifying donor organ-derived microvesicles from a biological sample of a subject. In certain embodiments, a method for isolating, purifying and / or identifying donor organ-derived microvesicles includes obtaining a biological sample from the subject and isolating, purifying or identifying a donor organ-derived microvesicle from the biological sample by the detection of a protein specific for the donor.

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and / or mobility, or alter normal cell growth and / or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods.

Disclosed herein are minimal arrestin domain containing protein 1 (ARRDC1) constructs, which drive the formation of ARRDC1-mediated microvesicles (ARMMs). These vesicles can be harnessed to package and deliver a variety of molecular cargos such as small molecules, nucleic acids, and proteins. An example of such cargo is the genome editor Cas9.

In a first aspect, the present invention relates to vaccines for preventing or treating protozoan parasite infections in an individual whereby the vaccine contains multiple protozoan variable surface antigens (VSAs) of said protozoan parasites microorganism. In particular, protective vaccines are disclosed. In a further aspect, a method for the preparation of the vaccine, in particular, the protective vaccine is described. The vaccine is composed of multiple distinguishable VSAs, preferably comprising the full repertoire of the different VSA encoded by the gene family in said protozoan parasite. In a second aspect, the present invention relates to vaccines for preventing or treating microbial infections in an individual whereby the vaccine contains microvesicles induced by confronting protozoan microorganisms with antibodies directed to their VSAs. In particular, protective vaccines are disclosed. The vaccine is composed of multiple antigens of said protozoan parasite. In a further aspect, methods for the preparation and administration of these vaccines, in particular, the protective vaccines are described.

The invention discloses a mesenchymal stem cell gel microvesicle as well as a preparation method and application thereof, the preparation method comprises the following steps: preparing a microvesicle suspension from enucleated cytoplasm by an extrusion method, re-suspending the microvesicle suspension by using a polyethylene glycol diacrylate gel monomer, freeze-thawing, re-suspending with PBS, centrifuging, and cross-linking with ultraviolet light to obtain the mesenchymal stem cell gel microvesicle. The mesenchymal stem cell gel microvesicle prepared by the invention has a good repair promoting effect on damaged tissues, can be efficiently absorbed by damaged tissue cells when being applied to a biological scene, promotes tissue repair through biological active factors carried by the mesenchymal stem cell gel microvesicle, can be used as a carrier material to be combined with other treatment medicines, and has a good application prospect. Wide application prospects are realized.

The invention relates to a construction method and application of mycobacterium tuberculosis lipoprotein labeled microvesicles, and belongs to the technical field of biological medicines. According to the invention, an extracellular structural domain of mycobacterium tuberculosis lipoprotein LpqH is fused with a transmembrane region and an intracellular region of vesicular stomatitis virus G protein through a genetic engineering means, and an LpqH48-159-VSVG fusion expression vector is constructed. After the carrier is transfected to mammalian cells, the microvesicles of which the surfaces are specifically marked with LpqH48-159 can be separated from cell culture supernatant by combining with an optimized gradient centrifugation method. The prepared microvesicles specifically target macrophages, and can be used as a novel carrier of mRNA vaccines, and experiments prove that the immune effect and the protective efficacy of the carrier in prevention of EV71 virus infection are significantly superior to those of traditional lipid nanoparticles, which reveals that the microvesicles provided by the invention have wide application prospects in the field of immunotherapy.

Provided is a microvesicle composition for reducing or inhibiting inflammatory expression, a method for preparing same, and use thereof. The composition comprises a mesenchymal stem cell microvesicle and a plant cell microvesicle. The plant is selected from any one of lonicera, schisandra, zingiber, astragalus, ophiopogon, panax, and momordica, or a combination thereof.

In a first aspect, the present invention relates to vaccines for preventing or treating protozoan parasite infections in an individual, whereby the vaccine contains multiple protozoan variable surface antigens (VSAs) of said protozoan parasite microorganism. In particular, protective vaccines are disclosed. In a further aspect, a method for the preparation of the vaccine, particularly the protective vaccine, is described. The vaccine comprises multiple distinguishable VSAs, preferably comprising the entire repertoire of the different VSAs encoded by the gene family in said protozoan parasite. In a second aspect, the present invention relates to vaccines for preventing or treating microbial infections in an individual, whereby the vaccine contains microvesicles induced by confronting protozoan microorganisms with antibodies directed to their VSAs. In particular, protective vaccines are disclosed. The vaccine is composed of multiple antigens of said protozoan parasite. In a further aspect, methods for the preparation and administration of these vaccines, particularly the protective vaccines, are described.

The application relates to the technical field of biological medicine manufacturing, and discloses a controlled-release type preparation composition for realizing ovary function recovery, which comprises a core active unit, a moisturizing slow-release unit and a plant extract component. The core active unit is an anisotropic core-shell structure microcapsule with asymmetric charge distribution, which is composed of chitosan, polyglutamic acid and an internal compound, and a layer of outwardly radiating carboxyl brush-shaped molecular chain is distributed on the surface of the core active unit. The moisturizing slow-release unit comprises a polymer skeleton formed by rosmarinic acid and hyaluronic acid, and the polymer skeleton internally occludes elemene. The application utilizes a kinetic restriction mechanism to construct an anisotropic surface layer topology, avoids mucus protein adsorption, induces anti-inflammatory immune regulation by physically adapting mucosal receptors, the moisturizing slow-release unit firstly constructs a physical barrier to repair damage, and the core active unit is used to realize component graded controlled release.

The invention is suitable for the technical field of biological medicine, and provides a cell microvesicle based on freezing extraction and an extraction method and application thereof, ginsenoside Rh2 is used for pre-stimulating human umbilical cord mesenchymal stem cells (hUC-MSCs), a freezing extraction technology is used for extracting cell-derived frozen microvesicles (CDCs), and the novel engineered vesicles Rh2-CDCs are prepared. The method can effectively improve in-vivo blood coagulation and fibrinolytic system functions, reduce multi-organ injury, improve the treatment effect and improve the biological stability of nano-drug treatment, and the freezing extraction technology not only greatly shortens the extraction time and reduces the production cost, but also can obtain the microvesicles with higher concentration, so that the microvesicles have better application prospects. The technical bottleneck of the traditional exosome in application is expected to be overcome; besides, the freezing extraction technology is also suitable for vesicle extraction of other types of cells, and the extracted CDCs can be used as a nano-particle platform to deliver other drugs and active ingredients, so that the freezing extraction method has a wide application prospect.

This present disclosure relates to the use of donor organ-derived microvesicles to monitor the status of a transplanted organ in a subject. Accordingly, this disclosure provides for methods and kits for isolating, purifying and / or identifying donor organ-derived microvesicles from a biological sample of a subject. In certain embodiments, a method for isolating, purifying and / or identifying donor organ-derived microvesicles includes obtaining a biological sample from the subject and isolating, purifying or identifying a donor organ-derived microvesicle from the biological sample by the detection of a protein specific for the donor.

The present disclosure generally relates to clean meat and other cultivated animal-derived products. In certain aspects, proteins are harvested from cell culture media (e.g., a protein suspension) being used to culture cells, such as non-human animal cells, to yield a protein isolate. Such cells may produce or secrete proteins, or other biological materials, that are solubilized, or insoluble but in suspension (e.g., exosomes or microvesicles), within the cell culture media, and such proteins, and other biological materials, can be recovered in certain cases (e.g., a protein isolate) and used to produce cultivated meat or other animal-derived products. Examples of soluble proteins in the protein suspension that can be removed from cell culture media include albumin. plasma proteins, other secreted proteins, or the like. Other aspects are generally directed to systems and methods for making or using such proteins, kits involving these, or the like.

The present invention provides methods, systems, compositions, and strategies for the use of ARMM-mediated delivery of molecules (e.g, biological molecules, small molecules, proteins, and nucleic acids), to cells of the nervous system. In particular, the present invention generally relates to compositions and methods of producing, testing, and administering ARRDC1-mediated microvesicles (“ARMMs”) to peripheral nervous system cells in mammalian subjects.

To provide a new system that allows introduction of a nucleic acid encoding a protein into a cell and enables enhancement of translation efficiency of the protein expressed from the introduced encoding nucleic acid.SOLUTION: An angiogenesis promoter of the present invention comprises a group of artificial microvesicles composed of multiple artificial microvesicles, the group of artificial microvesicles containing at least one microRNA selected from the group consisting of miR-126, miR-135, and miR-210. An ischemia therapeutic agent of the present invention comprises the angiogenesis promoter of the present invention.SELECTED DRAWING: Figure 1

Provided herein are methods, systems, and compositions for ARMMs-mediated treatment of ABCA4 retinopathies such as Stargardt disease (STGD1) and Fundus flavimaculatus (FFM).

The invention relates to an impact-resistant PE pipe and a preparation method thereof, and belongs to the technical field of polymer composite materials. The PE pipe is prepared from the following components in percentage by weight: 6.2 to 9.5 percent of calcium carbonate whisker, 4.4 to 5.8 percent of impact modifier, 0.2 to 0.3 percent of lubricant, 0.15 to 0.2 percent of antioxidant, 0.11 to 0.14 percent of ultraviolet light absorber, 2.6 to 3.2 percent of color master batch and the balance of polyethylene resin, a disulfide structure in a molecular chain of the anti-impact modifier is loaded among the calcium carbonate whiskers through chelation in a multi-point anchoring mode to form a strengthening and impact energy dispersing network, and meanwhile, polycyclohexyl chain segments in the molecular chain form a large number of microvesicle unit structures on the surfaces of the calcium carbonate whiskers. Impact energy is absorbed and is uniformly dispersed and transitionally transmitted by slippage deformation of the vesicle structure, so that the impact resistance of the PE pipe is effectively improved.

Therapeutic formulations and protocols for enhancement of hepatic regeneration, reduction / reversion of liver failure, and restoration of hepatic characteristics of young liver including augmented production of digestive enzymes, production of complement, and detoxificiation. In one embodiment endothelial progenitor cells are cultured in vitro under conditions capable of stimulating enhanced production of microvesicles such as exosomes and / or regenerative factors. Endothelial cells can be activated to produce regenerative factors and / or exosomes by exposure to toll like receptor agonists. Endothelial cells may be autologous, allogeneic or xenogeneic to the recipient.

The invention discloses a molecular marker APOE for predicting immunotherapy prognosis of bile duct cancer and application of the molecular marker APOE, and belongs to the technical field of biomedicine. The invention finds that APOE can be used as a molecular marker for predicting prognosis of bile duct cancer, and the overall survival rate of high expression of APOE in bile duct cancer serum microvesicles is obviously lower than that of an APOE low expression group. The invention provides a new marker for predicting the prognosis of the bile duct cancer and formulating a treatment scheme, which is of great significance for accurately predicting the prognosis risk of a patient and enriching the treatment strategy of the bile duct cancer.